M
8.60
0.48 (5.91%)
| Previous Close | 8.12 |
| Open | 8.10 |
| Volume | 428,740 |
| Avg. Volume (3M) | 485,379 |
| Market Cap | 692,221,696 |
| Price / Earnings (Forward) | 1.61 |
| Price / Sales | 23.67 |
| Price / Book | 228.30 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Operating Margin (TTM) | -2,159.71% |
| Diluted EPS (TTM) | -2.31 |
| Quarterly Revenue Growth (YOY) | 176.30% |
| Total Debt/Equity (MRQ) | 244.35% |
| Current Ratio (MRQ) | 1.52 |
| Operating Cash Flow (TTM) | -104.58 M |
| Levered Free Cash Flow (TTM) | -53.25 M |
| Return on Assets (TTM) | -37.28% |
| Return on Equity (TTM) | -216.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | MeiraGTx Holdings plc | Bearish | Bullish |
AIStockmoo Score
-0.4
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.38 |
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 24.27% |
| % Held by Institutions | 60.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sanofi | 30 Sep 2025 | 12,197,737 |
| Johnson & Johnson | 30 Sep 2025 | 6,641,064 |
| Knoll Capital Management, Llc | 30 Sep 2025 | 1,250,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (Chardan Capital, 306.98%) | Buy |
| Median | 29.00 (237.21%) | |
| Low | 16.00 (RBC Capital, 86.05%) | Buy |
| Average | 26.00 (202.33%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 8.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Nov 2025 | 20.00 (132.56%) | Buy | 7.57 |
| Chardan Capital | 14 Nov 2025 | 35.00 (306.98%) | Buy | 8.19 |
| 11 Nov 2025 | 35.00 (306.98%) | Buy | 8.90 | |
| RBC Capital | 14 Nov 2025 | 16.00 (86.05%) | Buy | 8.19 |
| Piper Sandler | 11 Nov 2025 | 30.00 (248.84%) | Buy | 8.90 |
| Raymond James | 21 Oct 2025 | 29.00 (237.21%) | Buy | 9.26 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2025 | Announcement | Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference |
| 13 Nov 2025 | Announcement | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results |
| 10 Nov 2025 | Announcement | MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology |
| 07 Oct 2025 | Announcement | MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |